US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IT Tech Packaging Inc

0.1999

+0.00231.16%

Volume:256.97K

Turnover:51.60K

Market Cap:3.39M

PE:-0.21

High:0.2025

Open:0.1972

Low:0.1962

Close:0.1976

Loading ...

Overview Company News Filings

Press Release: XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

Press Release: Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

IT Tech Packaging Inc. Announces $1.4 Million Public Offering of Common Stock

IT Tech Packaging Announces Pricing of $1.4 Million Public Offering

THOMSON REUTERS

Press Release: XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

Amex Halt Add Info Lst 0.770000

THOMSON REUTERS

International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease

Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

ACCESS Newswire

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

ACCESS Newswire

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting

Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ITP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ITP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITP\",,,,,undefined,":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.1999,"timestamp":1750178506321,"preClose":0.1976,"halted":0,"volume":256967,"delay":0,"floatShares":16423694,"shares":16965400,"eps":-0.96,"marketStatus":"Trading","change":0.0023,"latestTime":"06-17 12:46:41 EDT","open":0.1972,"high":0.2025,"low":0.1962,"amount":51599.31536611,"amplitude":0.031883,"askPrice":0.2,"askSize":100,"bidPrice":0.1971,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.96,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750190400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.1976,"preHourTrading":{"tag":"盘前","latestPrice":0.196,"preClose":0.1976,"latestTime":"09:12 EDT","volume":1986,"amount":390.64518714,"timestamp":1750165938407},"postHourTrading":{"tag":"盘后","latestPrice":0.1999,"preClose":0.22,"latestTime":"19:49 EDT","volume":111039,"amount":21675.4513,"timestamp":1750117768880},"volumeRatio":0.354433,"impliedVol":0.0711,"impliedVolPercentile":0.248},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITP\",,,,,undefined,":{"symbol":"ITP","floatShares":16423694,"roa":"-2.71%","roe":"-6.06%","lyrEps":-0.977863,"volumeRatio":0.354433,"shares":16965400,"dividePrice":0,"high":0.2025,"amplitude":0.031883,"preClose":0.1976,"low":0.1962,"week52Low":0.151,"pbRate":"0.02","psRate":"0.04","week52High":1.07,"institutionHeld":0,"latestPrice":0.1999,"eps":-0.96,"divideRate":0,"volume":256967,"delay":0,"ttmEps":-0.96,"open":0.1972,"prevYearClose":0.6014,"prevWeekClose":0.1989,"prevMonthClose":0.19,"prevQuarterClose":0.2739,"fiveDayClose":0.1955,"twentyDayClose":0.1744,"sixtyDayClose":0.286},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ITP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538346522","title":"Press Release: XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2538346522","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538346522?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:01","pubTimestamp":1748347260,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025  -- XOMA Royalty Corporation , the biotech royalty aggregator, and BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab  royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million.\"This transaction further builds the potential of XOMA Royalty's late-stage royalty portfolio by increasing our economics in a promising Phase 3 program already in our portfolio,\" stated Brad Sitko, Chief Investment Officer of XOMA Royalty.  \"We appreciate the longstanding relationship with BioInvent stemming from XOMA's legacy technology, which gave rise to mezagitamab.  We are pleased to provide BioInvent non-dilutive capital to further advance its proprietary pipeline to a key inflection point.\". In its ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","TM","BK4099","BK4022","ITP","BK4199","03160","BK4588","USD","BK4232","BK4139","R","BK4604","BK4585","XOMA"],"gpt_icon":0},{"id":"2535002797","title":"Press Release: Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002797","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002797?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:01","pubTimestamp":1747252860,"startTime":"0","endTime":"0","summary":"Conference call today, May 14, 2025, at 4:30 PM ET. SAN DIEGO, May 14, 2025  -- Bionano Genomics, Inc.  today reported financial results for the first quarter ended March 31, 2025.\"The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping  and VIA software as the primary drivers of our revenue and gross profit.   We are pleased to see consistent utilization of our OGM systems and software combined with a year-over-year growth in consumables purchased by our customers we consider to be routine users of OGM. After significant reductions in costs and cash burn, together with our gross margin improvements, we have been able to extend cash runway, while at the same time, the global community of OGM users continues to publish groundbreaking research that demonstrates the value of OGM and VIA software in cytogenomics. We believe the operational efficiency and market development succes","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","BK4604","03160","LU2065732104.USD","TM","BK4575","BK4099","BK4588","BK4555","BNGO","BK4199","ITP","BK4097","BK4121","BK4585"],"gpt_icon":0},{"id":"2535042243","title":"Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042243?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus  on Track to Initiate in 2025. CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025. Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer. Strong Financial Position, with Cash Runway Expected Through 2027. \"2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,\" said Aoife Brennan, President and CEO of Climb Bio. \"Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4539","SLE","CLYM","ITP","CTA","BK4199","BK4139"],"gpt_icon":0},{"id":"2535630720","title":"IT Tech Packaging Inc. Announces $1.4 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2535630720","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535630720?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:15","pubTimestamp":1747138521,"startTime":"0","endTime":"0","summary":"IT Tech Packaging Inc., a leading manufacturer and distributor of diversified paper products in North China, has announced the pricing of a public offering of 6,899,500 shares of its common stock at a price of $0.20 per share. The offering is expected to generate approximately $1.4 million in gross proceeds for the company, prior to the deduction of offering fees and expenses. Maxim Group LLC is serving as the sole placement agent for this offering. The company plans to utilize the net proceeds for working capital and other general corporate purposes. A shelf registration statement for the shares was filed with the SEC and declared effective in April 2023. The offering is being conducted through a written prospectus and prospectus supplement, which are available on the SEC's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL2lvrFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2535072050","title":"IT Tech Packaging Announces Pricing of $1.4 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2535072050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535072050?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:15","pubTimestamp":1747138505,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA2SW51D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2535872106","title":"Press Release: XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2535872106","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535872106?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:30","pubTimestamp":1747135800,"startTime":"0","endTime":"0","summary":"Pipeline advancements: The Marketing Authorization Application  for Day One Biopharmaceuticals and Ipsen's tovorafenib was accepted for review by the European Marketing Authority  and Takeda initiated its Phase 3 trial exploring mezagitamab for the treatment of chronic primary immune thrombocytopenia. Business development: Acquired an economic interest in Castle Creek Biosciences' D-Fi  through participation in a syndicated royalty financing transaction and successfully sold all unpartnered Kinnate assets. Cash receipts: Received $18.0 million in the first quarter of 2025 including $13.4 million in royalty receipts. EMERYVILLE, Calif. , May 13, 2025  -- XOMA Royalty Corporation , the biotech royalty aggregator, reported its first quarter 2025 financial results and highlighted recent actions that have the potential to deliver shareholder value.\"We are committed to generating value for shareholders through prudent cash deployment, strict expense control, and opportunistic share repurchas","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MAA","BK4215","R","BK4199","BK4588","XOMA","BK4192","BK4232","BK4022","ITP","BK4139"],"gpt_icon":0},{"id":"2534345633","title":"Amex Halt  Add Info Lst 0.770000","url":"https://stock-news.laohu8.com/highlight/detail?id=2534345633","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534345633?lang=en_us&edition=fundamental","pubTime":"2025-05-10 01:33","pubTimestamp":1746811990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nAQN2KDK15:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2532822701","title":"International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2532822701","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532822701?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:30","pubTimestamp":1746192600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 02, 2025  -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc.  that offers CLIA-certified laboratory developed tests  based on optical genome mapping , today announcedthe publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping  for the integration of OGM as a standard-of-care  cytogenetic assay for diagnostic workflows in various clinical settings.Nineteen  experts from the ICOGM, representing relevant multidisciplinary fields, conducted an in-depth review of the classification of hematolymphoid malignancies using the World Health Organization  and ICC  criteria and published studies of OGM performance to assess whether OGM could provide a comprehensive analysis of the genome sufficient for better diagnosis, prognosis and treatment compared to existing SOC workflows across several indications. Based on the assessment, the ICOGM developed a set of expert recommendatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/international-consortium-optical-genome-mapping-133000963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2413666699.HKD","CCS","IE00BN0W2V16.EUR","LU1543694498.USD","BK4588","BK4199","LU1721428933.USD","LU2041044095.USD","OCC","BK4575","BK4088","IE00BN0W2T93.GBP","BK4121","BK4020","BK4589","CMA","BK4207","BK4124","ITP","BK4585","LU2089279066.USD","BNGO","A","LU2092937221.SGD","SOC","LU2229751404.USD","LU2413666426.HKD","SMP","IE00BN0W2W23.USD","BK4213","BK4211","LU0347712357.USD","BK4567","LU1165135440.EUR"],"gpt_icon":0},{"id":"2529507685","title":"Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2529507685","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529507685?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 23, 2025  -- Bionano Genomics, Inc. today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping  can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation  linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud University Medical Center in the Netherlands, the study provides one of the most comprehensive evaluations to date of OGM as a single workflow for characterizing large repeat expansions. Researchers evaluated 85 subjects containing known pathogenic expansions in three genes, DMPK , CNBP , and RFC1 . DM isa genetic condition causing progressive muscle weakness and wasting, affecting both skeletal and smooth muscles and CANVAS is a genetic condition characterized by progressive loss of coordination, sensory nerve damage, and impaired balance reflexes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bionano-announces-publication-showing-ogm-120000793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4575","BNGO","DM","ITP","BK4121","BK4161","NGS","BK4199","BK4546","BK4179"],"gpt_icon":0},{"id":"2525899597","title":"Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899597","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899597?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  08, 2025  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057546/0/en/Bionano-Announces-French-Publication-of-an-Effective-Method-for-Analysis-of-Multiple-Myeloma-by-OGM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2525248895","title":"BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525248895","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525248895?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:15","pubTimestamp":1744110900,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's  initiation of Phase 3 clinical trial of mezagitamab , identified from BioInvent's proprietary n-CoDeR antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia .\"We are excited to see mezagitamab progress into Phase 3 trials, marking a significant step for Takeda and our n-CoDeR platform,\" said Martin Welschof, Chief Executive Officer of BioInvent. \"This milestone not only validates the consistent high quality of drug candidates identified from our n-CoDeR antibody library, but it also highlights the success of our out-licensing strategy and its ability to drive real-world impact t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-milestone-payment-takeda-111500286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOVNF","TAK","BK4007","XOMA","ITP","BK4199","BK4139"],"gpt_icon":0},{"id":"2524595405","title":"Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2524595405","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524595405?lang=en_us&edition=fundamental","pubTime":"2025-04-03 13:00","pubTimestamp":1743656400,"startTime":"0","endTime":"0","summary":"Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease. Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia. Paris, April 3, 2025. The US Food and Drug Administration  has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kinase  inhibitor, for two rare diseases, warm autoimmune hemolytic anemia  and IgG4-related disease . There is still a significant unmet medical need for these two rare diseases, and neither have any currently approved medicine. FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US.About rilzabrutinib Rilzabrutinib is an investigational, oral, reversible, BTK inhibitor that has the potential to be a first- and best-in-class treatment of several immune-mediated diseases. BTK, expressed in B cells, mac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/press-release-rilzabrutinib-granted-orphan-050000915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITP","BK4588","IE00BFXG1179.USD","BK4007","BK4199","SNY","BK4585"],"gpt_icon":0},{"id":"2524749829","title":"Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524749829","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524749829?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:01","pubTimestamp":1743451260,"startTime":"0","endTime":"0","summary":"Conference call today, March 31, 2025 at 4:30 PM ETSAN DIEGO, March  31, 2025  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and ful","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052748/0/en/Bionano-Reports-Fourth-Quarter-and-Full-Year-2024-Results-and-Provides-Revenue-Outlook-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4208","LU1894683264.USD","LU2346227817.USD","LU2500361329.USD","ITP","LU2637428348.USD","BK4199","BK4585","CMS","LU1894683348.USD","BK4588"],"gpt_icon":0},{"id":"2523947806","title":"CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523947806","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523947806?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:15","pubTimestamp":1743423300,"startTime":"0","endTime":"0","summary":"BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024.Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, \"2024 was a transformative year for CASI as we strategically pivoted our company toward the development of CID-103 for organ transplant rejection and autoimmune disease. CID-103 is an anti-CD38 antibody with the potential to be a best-in-class treatment for a myriad of autoimmune diseases as well as antibody mediated rejection . We are encouraged by our clinical progress, achieving a milestone with the first Immune Thrombocytopenia  patient dosed in January 2025. Simultaneously, we are diligently working towards resolution of the FDA renal allograft ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/casi-pharmaceuticals-announces-fourth-quarter-121500480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CASI","CTA","ITP","BK4139","BK4199","BK4585","BK4006","BK4017","BK4588","AMR","CDE"],"gpt_icon":0},{"id":"2522372236","title":"Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522372236","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522372236?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:05","pubTimestamp":1743077100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc.  resolving patent litigation related to Rigel's product TAVALISSE . The litigation resulted from submission by Annora of an Abbreviated New Drug Application to theU.S. Food and Drug Administration seeking approval to market a generic version of TAVALISSE inthe United States. Under the terms of the settlement agreement, Annora will have a license to sell its generic product in Q2 2032 or earlier under certain circumstances. In accordance with the agreement, the parties terminated all ongoing litigation between Rigel and Annora regarding TAVALISSE patents pending in New Jersey.\"The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia,\" said R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rigel-announces-settlement-agreement-resolving-120500257.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rigel-announces-settlement-agreement-resolving-120500257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4199","ITP","RIGL","BK4139"],"gpt_icon":0},{"id":"2522359149","title":"Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2522359149","media":"Exec Edge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522359149?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:38","pubTimestamp":1743021535,"startTime":"0","endTime":"0","summary":"Climb Bio, Inc.  reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.As we highlighted in our 66-page initiation report last week , CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy , systemic lupus erythematosus and lupus nephritis , and immune thrombocytopenia . The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4199","ITP","CLYM","BK4139"],"gpt_icon":0},{"id":"2522887962","title":"Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887962?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:05","pubTimestamp":1742933100,"startTime":"0","endTime":"0","summary":"Received Clearance from the U.S. Food and Drug Administration  for Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus . Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position. Expanded Pipeline to Include CLYM116, an Anti-APRIL  Monoclonal Antibody for Treatment of IgA Nephropathy . Appointed Perrin Wilson, Ph.D. as Chief Business Officer. Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027. received clearance from the FDA to initiate a Phase 2 clinical trial of. budoprutug in patients with pMN. This open-label, dose-ranging","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4139","BK4199","BK4077","CLYM","SLE"],"gpt_icon":0},{"id":"2521747672","title":"Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747672","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747672?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, and GREENWOOD, S.C., March 24, 2025  -- Bionano Genomics, Inc. and Greenwood Genetic Center  today announced a publication in Genome Research describing the first study to use optical genome mapping  to investigate the genetic landscape of neural tube defects . NTDs are the most common birth defect of the central nervous system and some of the most devastating congenital conditions. Despite an expected genetic link in as many as 60-70% of cases, methods currently in use, including karyotyping , chromosomal microarray  and next-generation sequencing , collectively identify pathogenic gene variants in only about 8% of cases, suggesting more work is needed to better understand the underlying genetic drivers of NTDs.In this GGC study, OGM was used to provide a comprehensive, genome-wide analysis of structural variants  across a study cohort of 104 NTD cases. The key findings include:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-using-ogm-neural-tube-120000906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","NGS","LU0541501648.USD","BK4588","BK4121","BK4179","BK4211","BK4575","CMA","BK4199","ITP","LU0541502299.USD","BNGO","KT","BK4207","BK4115","BK4589"],"gpt_icon":0},{"id":"2520605180","title":"Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2520605180","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520605180?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"Featured Scientific Session: \"Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory\", an accredited continuing medical education  session, with a panel of experts presenting research on OGM's clinical and translational applications.Dr. Adam Smith  will provide an overview of OGM’s evolution into an essential tool for hematological malignancy research and its role in research of pre- and post-natal constitutional genetic disease.Dr. Laila El-Khattabi  will share results from the CHROMAPS project, a multi-institutional European collaboration utilizing OGM to evaluate structural variations and aneuploidies in constitutional and reproductive disorders.Dr. Nikhil S. Sahajpal  will present OGM findings from three clinical research cohorts, including neural tube defects , undiagnosed rare disorders, and prenatal cases.Dr. Rashmi Kanagal-Shamanna  will showcase an integrated approach combining OGM and targeted NGS for hematologic malignancies,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bionano-announces-extensive-lineup-content-120000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","LU2506952170.USD","LU0823417737.USD","LU1732799900.SGD","IE00BDGV0183.EUR","LU1599440770.SGD","IE00BVYPNV92.GBP","IE00B3T34201.USD","LU0731783394.SGD","IE00B42XCP33.USD","IE00BVYPNW00.USD","LU0795875169.SGD","LU2023251221.USD","IE00BGHQF631.EUR","BK4112","LU2347655156.SGD","LU2506951875.HKD","LU0158827948.USD","LU0265550946.USD","IE00B3PB1722.GBP","LU2506951958.HKD","LU0772969993.USD","BNGO","LU0950375773.USD","LU2133065610.SGD","BK4575","LU1481011671.HKD","LU0795875086.SGD","LU2089284900.SGD","LU1116320737.USD","LU1718418525.SGD","LU0731783048.USD","BK4561","LU0912757837.SGD","LU2506952097.USD","LU0742537680.HKD","BK4588","LU2089283258.USD","CME","LU0823417653.USD","AFG","BK4566","ITP","LU2237438978.USD","LU1116320901.HKD","BK4585","BK4199","LU0265550359.USD","BK4107","LU1732800096.USD"],"gpt_icon":1},{"id":"2519831939","title":"Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2519831939","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519831939?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:00","pubTimestamp":1741870800,"startTime":"0","endTime":"0","summary":"In-Motion Webinar: Bionano will host a webinar featuring the study’s lead author, Dr. Guilin Tang, who will discuss the study and its findings in detail, including a summary of the potential implicati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042236/0/en/Bionano-Announces-Publication-Reporting-First-Use-of-OGM-to-Detect-Chromoanagenesis-a-Key-Marker-of-Poor-Prognosis-in-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAG","BK4212","BK4524","ITP","BK4199","BK4585","LU1571399168.USD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ITP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-09","symbol":"ITP","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"post","actualEps":-0.35},{"market":"US","date":"2025-04-11","symbol":"ITP","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1744344000000,"reportTimeType":"post","actualEps":-0.4},{"market":"US","date":"2024-11-15","symbol":"ITP","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731646800000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2024-08-12","symbol":"ITP","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"post","actualEps":-0.01},{"market":"US","date":"2024-05-10","symbol":"ITP","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"post","actualEps":-0.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ITP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ITP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ITP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ITP","date":"2025-06-16","current":-0.35149,"percent":0.380719,"low":-44.225896,"twenty":-6.370535,"median":-0.267269,"eighty":2.563432,"high":54.69137,"avg":-1.60156,"sd":10.670524,"marketCap":3374422},"quantilePoints":[{"date":"2020-06-19","current":6.131703,"twenty":-2.764419,"median":1.996689,"eighty":2.825237,"marketCap":15375185},{"date":"2020-06-26","current":6.071433,"twenty":-2.764419,"median":1.996689,"eighty":3.352753,"marketCap":15224057},{"date":"2020-07-02","current":6.707119,"twenty":-2.764419,"median":1.996689,"eighty":3.392735,"marketCap":16818034},{"date":"2020-07-10","current":6.976632,"twenty":-2.764419,"median":1.996689,"eighty":3.395451,"marketCap":17493835},{"date":"2020-07-17","current":6.479682,"twenty":-2.764419,"median":1.996854,"eighty":3.44078,"marketCap":16247738},{"date":"2020-07-24","current":5.534681,"twenty":-2.764419,"median":1.996854,"eighty":3.480337,"marketCap":13878158},{"date":"2020-07-31","current":5.5961,"twenty":-2.764419,"median":1.996961,"eighty":3.52278,"marketCap":14032166},{"date":"2020-08-07","current":5.690475,"twenty":-2.764419,"median":1.996961,"eighty":3.574051,"marketCap":14268810},{"date":"2020-08-14","current":12.169336,"twenty":-2.764419,"median":1.996961,"eighty":3.607667,"marketCap":13111109},{"date":"2020-08-21","current":11.962897,"twenty":-2.764419,"median":1.996961,"eighty":3.647309,"marketCap":12888694},{"date":"2020-08-28","current":11.430892,"twenty":-2.764419,"median":1.996961,"eighty":3.692553,"marketCap":12315517},{"date":"2020-09-04","current":11.256239,"twenty":-2.764419,"median":1.996961,"eighty":3.696797,"marketCap":12127348},{"date":"2020-09-11","current":11.804098,"twenty":-2.764419,"median":1.996961,"eighty":3.706375,"marketCap":12717605},{"date":"2020-09-18","current":12.703988,"twenty":-2.764419,"median":1.996961,"eighty":3.734996,"marketCap":13687137},{"date":"2020-09-25","current":12.703961,"twenty":-2.764419,"median":1.996961,"eighty":3.791963,"marketCap":13687108},{"date":"2020-10-02","current":13.402679,"twenty":-2.764419,"median":1.996961,"eighty":3.91983,"marketCap":14439899},{"date":"2020-10-09","current":13.497959,"twenty":-2.764419,"median":1.996961,"eighty":3.973474,"marketCap":14542553},{"date":"2020-10-16","current":14.927154,"twenty":-2.764419,"median":1.996961,"eighty":4.10837,"marketCap":16082352},{"date":"2020-10-23","current":14.559269,"twenty":-2.764419,"median":1.996961,"eighty":4.120981,"marketCap":15685996},{"date":"2020-10-30","current":19.482054,"twenty":-2.764419,"median":1.996961,"eighty":4.148109,"marketCap":20989751},{"date":"2020-11-06","current":17.203017,"twenty":-2.764419,"median":1.996961,"eighty":4.181008,"marketCap":18534341},{"date":"2020-11-13","current":-9.603037,"twenty":-2.839145,"median":1.996961,"eighty":4.224806,"marketCap":17108886},{"date":"2020-11-20","current":-9.763088,"twenty":-2.962427,"median":1.996689,"eighty":4.224806,"marketCap":17394034},{"date":"2020-11-27","current":-10.901047,"twenty":-3.03429,"median":1.996689,"eighty":4.224806,"marketCap":19421437},{"date":"2020-12-04","current":-10.421376,"twenty":-3.145907,"median":1.995039,"eighty":4.224806,"marketCap":18566848},{"date":"2020-12-11","current":-10.505722,"twenty":-3.248615,"median":1.980353,"eighty":4.224806,"marketCap":18717121},{"date":"2020-12-18","current":-10.830625,"twenty":-3.389217,"median":1.976914,"eighty":4.224806,"marketCap":19295971},{"date":"2020-12-24","current":-9.242923,"twenty":-3.442179,"median":1.958923,"eighty":4.224806,"marketCap":16467302},{"date":"2020-12-31","current":-8.906816,"twenty":-3.460299,"median":1.953656,"eighty":4.224806,"marketCap":15868491},{"date":"2021-01-08","current":-10.243239,"twenty":-3.559086,"median":1.94893,"eighty":4.224806,"marketCap":18249478},{"date":"2021-01-15","current":-17.536796,"twenty":-3.633486,"median":1.940147,"eighty":4.224806,"marketCap":31243766},{"date":"2021-01-22","current":-24.155324,"twenty":-3.673791,"median":1.922398,"eighty":4.224806,"marketCap":43035415},{"date":"2021-01-29","current":-23.795989,"twenty":-3.709749,"median":1.921487,"eighty":4.224806,"marketCap":42395219},{"date":"2021-02-05","current":-25.813796,"twenty":-3.763075,"median":1.914177,"eighty":4.224806,"marketCap":45990168},{"date":"2021-02-12","current":-33.476546,"twenty":-3.800839,"median":1.89768,"eighty":4.224806,"marketCap":59642216},{"date":"2021-02-19","current":-37.776286,"twenty":-3.806501,"median":1.877009,"eighty":4.224806,"marketCap":67302684},{"date":"2021-02-26","current":-40.860672,"twenty":-3.833611,"median":1.858424,"eighty":4.224806,"marketCap":72797864},{"date":"2021-03-05","current":-34.116363,"twenty":-3.854686,"median":1.839016,"eighty":4.231544,"marketCap":60782121},{"date":"2021-03-12","current":-39.097525,"twenty":-3.878378,"median":1.821163,"eighty":4.231544,"marketCap":69656619},{"date":"2021-03-19","current":-39.400397,"twenty":-3.892317,"median":1.799513,"eighty":4.231544,"marketCap":70196220},{"date":"2021-03-26","current":-13.603798,"twenty":-3.892836,"median":1.765502,"eighty":4.224806,"marketCap":75555524},{"date":"2021-04-01","current":-14.113174,"twenty":-3.899064,"median":1.749149,"eighty":4.224806,"marketCap":78384595},{"date":"2021-04-09","current":-12.718017,"twenty":-3.936349,"median":1.735281,"eighty":4.231544,"marketCap":70635894},{"date":"2021-04-16","current":-10.432988,"twenty":-4.013427,"median":1.724549,"eighty":4.231544,"marketCap":57944838},{"date":"2021-04-23","current":-11.159206,"twenty":-4.103049,"median":1.709963,"eighty":4.231544,"marketCap":61978253},{"date":"2021-04-30","current":-11.425145,"twenty":-4.175407,"median":1.709615,"eighty":4.231544,"marketCap":63455278},{"date":"2021-05-07","current":-10.283653,"twenty":-4.247292,"median":1.693831,"eighty":4.231544,"marketCap":57115431},{"date":"2021-05-14","current":-5.977608,"twenty":-4.25332,"median":1.693831,"eighty":4.231544,"marketCap":44572455},{"date":"2021-05-21","current":-6.446518,"twenty":-4.299998,"median":1.693831,"eighty":4.231544,"marketCap":48068916},{"date":"2021-05-28","current":-6.328294,"twenty":-4.300383,"median":1.693831,"eighty":4.231544,"marketCap":47187372},{"date":"2021-06-04","current":-6.656398,"twenty":-4.342234,"median":1.687217,"eighty":4.231544,"marketCap":49633904},{"date":"2021-06-11","current":-6.802517,"twenty":-4.353474,"median":1.677699,"eighty":4.231544,"marketCap":50723453},{"date":"2021-06-18","current":-6.053324,"twenty":-4.406565,"median":1.669633,"eighty":4.231544,"marketCap":45137039},{"date":"2021-06-25","current":-6.309697,"twenty":-4.441074,"median":1.645436,"eighty":4.231544,"marketCap":47048702},{"date":"2021-07-02","current":-6.243279,"twenty":-4.459656,"median":1.6264,"eighty":4.231544,"marketCap":46553453},{"date":"2021-07-09","current":-5.931115,"twenty":-4.475796,"median":-1.295272,"eighty":4.231544,"marketCap":44225780},{"date":"2021-07-16","current":-5.556518,"twenty":-4.508712,"median":-1.324768,"eighty":4.231544,"marketCap":41432573},{"date":"2021-07-23","current":-5.609652,"twenty":-4.560831,"median":-1.334002,"eighty":4.231544,"marketCap":41828772},{"date":"2021-07-30","current":-5.802264,"twenty":-4.574333,"median":-1.343919,"eighty":4.231544,"marketCap":43264996},{"date":"2021-08-06","current":-5.5791,"twenty":-4.629123,"median":-1.369008,"eighty":4.231544,"marketCap":41600958},{"date":"2021-08-13","current":-6.117555,"twenty":-4.75548,"median":-1.379088,"eighty":4.231544,"marketCap":42393357},{"date":"2021-08-20","current":-5.698759,"twenty":-4.910213,"median":-1.396833,"eighty":4.231544,"marketCap":39491195},{"date":"2021-08-27","current":-5.80453,"twenty":-4.974652,"median":-1.444588,"eighty":4.231544,"marketCap":40224164},{"date":"2021-09-03","current":-6.250483,"twenty":-5.129159,"median":-1.472287,"eighty":4.231544,"marketCap":43314521},{"date":"2021-09-10","current":-6.21332,"twenty":-5.186646,"median":-1.478896,"eighty":4.231544,"marketCap":43056991},{"date":"2021-09-17","current":-5.860274,"twenty":-5.25233,"median":-1.528269,"eighty":4.231544,"marketCap":40610459},{"date":"2021-09-24","current":-5.3743,"twenty":-5.326195,"median":-1.621324,"eighty":4.231544,"marketCap":37242762},{"date":"2021-10-01","current":-5.470066,"twenty":-5.366423,"median":-1.6265,"eighty":4.231544,"marketCap":37906396},{"date":"2021-10-08","current":-5.191345,"twenty":-5.366423,"median":-1.643757,"eighty":4.231544,"marketCap":35974923},{"date":"2021-10-15","current":-5.058417,"twenty":-5.366423,"median":-1.655582,"eighty":4.231544,"marketCap":35053759},{"date":"2021-10-22","current":-5.144177,"twenty":-5.379222,"median":-1.67206,"eighty":4.231544,"marketCap":35648059},{"date":"2021-10-29","current":-5.733063,"twenty":-5.421411,"median":-1.679496,"eighty":4.231544,"marketCap":39728914},{"date":"2021-11-05","current":-5.867421,"twenty":-5.446053,"median":-1.708151,"eighty":4.231544,"marketCap":40659983},{"date":"2021-11-12","current":-7.649226,"twenty":-5.510182,"median":-1.771965,"eighty":4.231544,"marketCap":37222952},{"date":"2021-11-19","current":-7.891444,"twenty":-5.545529,"median":-1.890196,"eighty":4.231544,"marketCap":38401646},{"date":"2021-11-26","current":-6.78823,"twenty":-5.576975,"median":-1.918737,"eighty":4.231544,"marketCap":33033141},{"date":"2021-12-03","current":-5.139514,"twenty":-5.621608,"median":-1.980081,"eighty":4.231544,"marketCap":25010099},{"date":"2021-12-10","current":-5.546604,"twenty":-5.706665,"median":-2.004536,"eighty":4.231544,"marketCap":26991097},{"date":"2021-12-17","current":-5.1904,"twenty":-5.706665,"median":-2.005005,"eighty":4.231544,"marketCap":25257724},{"date":"2021-12-23","current":-5.292173,"twenty":-5.706665,"median":-2.049487,"eighty":4.231544,"marketCap":25752974},{"date":"2021-12-31","current":-4.681538,"twenty":-5.706665,"median":-2.067662,"eighty":4.231544,"marketCap":22781477},{"date":"2022-01-07","current":-4.583836,"twenty":-5.70403,"median":-2.096797,"eighty":4.224806,"marketCap":22306037},{"date":"2022-01-14","current":-4.477789,"twenty":-5.70403,"median":-2.109955,"eighty":4.224806,"marketCap":21789987},{"date":"2022-01-21","current":-3.981342,"twenty":-5.70403,"median":-2.128125,"eighty":4.224806,"marketCap":19374160},{"date":"2022-01-28","current":-3.541685,"twenty":-5.701394,"median":-2.13099,"eighty":4.218068,"marketCap":17234682},{"date":"2022-02-04","current":-4.15232,"twenty":-5.701394,"median":-2.16371,"eighty":4.218068,"marketCap":20206179},{"date":"2022-02-11","current":-4.072938,"twenty":-5.701394,"median":-2.192974,"eighty":4.218068,"marketCap":19819884},{"date":"2022-02-18","current":-4.111611,"twenty":-5.701394,"median":-2.22164,"eighty":4.218068,"marketCap":20008079},{"date":"2022-02-25","current":-3.596642,"twenty":-5.701394,"median":-2.252185,"eighty":4.218068,"marketCap":17502117},{"date":"2022-03-04","current":-4.070902,"twenty":-5.701394,"median":-2.255631,"eighty":4.218068,"marketCap":19809980},{"date":"2022-03-11","current":-4.103469,"twenty":-5.701394,"median":-2.269351,"eighty":4.218068,"marketCap":19968459},{"date":"2022-03-18","current":26.328425,"twenty":-5.701394,"median":-2.274427,"eighty":4.278711,"marketCap":23841310},{"date":"2022-03-25","current":24.933795,"twenty":-5.701394,"median":-2.274427,"eighty":4.321864,"marketCap":22578424},{"date":"2022-04-01","current":25.048647,"twenty":-5.701394,"median":-2.274427,"eighty":4.355367,"marketCap":22682427},{"date":"2022-04-08","current":24.064203,"twenty":-5.701394,"median":-2.274427,"eighty":4.379783,"marketCap":21790978},{"date":"2022-04-14","current":23.079757,"twenty":-5.701394,"median":-2.274427,"eighty":4.384296,"marketCap":20899528},{"date":"2022-04-22","current":31.020945,"twenty":-5.701394,"median":-2.274427,"eighty":4.413473,"marketCap":28090551},{"date":"2022-04-29","current":49.397245,"twenty":-5.701394,"median":-2.274427,"eighty":4.446144,"marketCap":44730934},{"date":"2022-05-06","current":44.16875,"twenty":-5.701394,"median":-2.274427,"eighty":4.489378,"marketCap":39996349},{"date":"2022-05-13","current":6.141705,"twenty":-5.701394,"median":-2.274427,"eighty":4.589887,"marketCap":16927627},{"date":"2022-05-20","current":5.390614,"twenty":-5.701394,"median":-2.274427,"eighty":4.684477,"marketCap":14857485},{"date":"2022-05-27","current":5.642175,"twenty":-5.701394,"median":-2.274427,"eighty":4.716689,"marketCap":15550834},{"date":"2022-06-03","current":6.199205,"twenty":-5.701394,"median":-2.274427,"eighty":4.751784,"marketCap":17086107},{"date":"2022-06-10","current":7.187485,"twenty":-5.701394,"median":-2.274427,"eighty":4.885142,"marketCap":19809980},{"date":"2022-06-17","current":6.324986,"twenty":-5.701394,"median":-2.274427,"eighty":4.984328,"marketCap":17432782},{"date":"2022-06-24","current":6.084206,"twenty":-5.70403,"median":-2.2785,"eighty":5.183614,"marketCap":16769148},{"date":"2022-07-01","current":4.319678,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":11905797},{"date":"2022-07-08","current":3.773429,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":10400239},{"date":"2022-07-15","current":3.270305,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":9013540},{"date":"2022-07-22","current":3.665617,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":10103089},{"date":"2022-07-29","current":3.522227,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":9707880},{"date":"2022-08-05","current":3.917179,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":10796439},{"date":"2022-08-12","current":3.495928,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":10213397},{"date":"2022-08-19","current":3.394106,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":9915920},{"date":"2022-08-26","current":3.32826,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":9723551},{"date":"2022-09-02","current":3.156179,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":9220814},{"date":"2022-09-09","current":3.129704,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":9143469},{"date":"2022-09-16","current":2.952872,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":8626850},{"date":"2022-09-23","current":2.664203,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":7783501},{"date":"2022-09-30","current":2.639596,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":7711610},{"date":"2022-10-07","current":2.57952,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":7536099},{"date":"2022-10-14","current":2.50451,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":7316957},{"date":"2022-10-21","current":2.409815,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":7040303},{"date":"2022-10-28","current":2.376892,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":6944118},{"date":"2022-11-04","current":2.392844,"twenty":-5.70403,"median":-2.2785,"eighty":5.20675,"marketCap":6990723},{"date":"2022-11-11","current":-16.165639,"twenty":-5.72363,"median":-2.286959,"eighty":5.20675,"marketCap":8218320},{"date":"2022-11-18","current":-14.596009,"twenty":-5.78938,"median":-2.317974,"eighty":5.20675,"marketCap":7420348},{"date":"2022-11-25","current":-14.596009,"twenty":-5.807079,"median":-2.337619,"eighty":5.20675,"marketCap":7420348},{"date":"2022-12-02","current":-14.146899,"twenty":-5.833009,"median":-2.359058,"eighty":5.20675,"marketCap":7192029},{"date":"2022-12-09","current":-14.596009,"twenty":-5.862786,"median":-2.398421,"eighty":5.20675,"marketCap":7420348},{"date":"2022-12-16","current":-13.697792,"twenty":-5.870464,"median":-2.4436,"eighty":5.20675,"marketCap":6963711},{"date":"2022-12-23","current":-12.575022,"twenty":-5.888709,"median":-2.470374,"eighty":5.20675,"marketCap":6392915},{"date":"2022-12-30","current":-10.333973,"twenty":-5.922308,"median":-2.526018,"eighty":5.20675,"marketCap":5253606},{"date":"2023-01-06","current":-12.352713,"twenty":-5.947381,"median":-2.621176,"eighty":5.20675,"marketCap":6279897},{"date":"2023-01-13","current":-14.596009,"twenty":-5.966552,"median":-2.807167,"eighty":5.183614,"marketCap":7420348},{"date":"2023-01-20","current":-13.248683,"twenty":-5.977608,"median":-2.949874,"eighty":5.183614,"marketCap":6735392},{"date":"2023-01-27","current":-14.265891,"twenty":-6.018643,"median":-3.027804,"eighty":5.082249,"marketCap":7252522},{"date":"2023-02-03","current":-13.731476,"twenty":-6.056719,"median":-3.138164,"eighty":5.082249,"marketCap":6980835},{"date":"2023-02-10","current":-13.37221,"twenty":-6.078219,"median":-3.222835,"eighty":5.082249,"marketCap":6798191},{"date":"2023-02-17","current":-12.822031,"twenty":-6.113288,"median":-3.389217,"eighty":5.082249,"marketCap":6518490},{"date":"2023-02-24","current":-12.350469,"twenty":-6.134351,"median":-3.435644,"eighty":5.082249,"marketCap":6278756},{"date":"2023-03-03","current":-12.350469,"twenty":-6.147802,"median":-3.460299,"eighty":5.082249,"marketCap":6278756},{"date":"2023-03-10","current":-10.890867,"twenty":-6.181225,"median":-3.546126,"eighty":5.082249,"marketCap":5536721},{"date":"2023-03-17","current":-10.554036,"twenty":-6.240888,"median":-3.608889,"eighty":5.082249,"marketCap":5365482},{"date":"2023-03-24","current":-0.242972,"twenty":-6.317136,"median":-3.633313,"eighty":5.082249,"marketCap":4026368},{"date":"2023-03-31","current":-0.227847,"twenty":-6.313416,"median":-3.633313,"eighty":5.051335,"marketCap":3775726},{"date":"2023-04-06","current":-0.252084,"twenty":-6.317136,"median":-3.633313,"eighty":5.082249,"marketCap":4177356},{"date":"2023-04-14","current":-0.252266,"twenty":-6.320855,"median":-3.633529,"eighty":5.113162,"marketCap":4180376},{"date":"2023-04-21","current":-0.297337,"twenty":-6.320855,"median":-3.633529,"eighty":4.494334,"marketCap":4927267},{"date":"2023-04-28","current":-0.285492,"twenty":-6.320855,"median":-3.633529,"eighty":4.101236,"marketCap":4730982},{"date":"2023-05-05","current":-0.312799,"twenty":-6.320855,"median":-3.633529,"eighty":3.794992,"marketCap":5183495},{"date":"2023-05-12","current":-0.309497,"twenty":-6.320855,"median":-3.633313,"eighty":3.651242,"marketCap":5128777},{"date":"2023-05-19","current":-0.281334,"twenty":-6.324575,"median":-3.596642,"eighty":3.658429,"marketCap":4730982},{"date":"2023-05-25","current":-0.271697,"twenty":-6.328294,"median":-3.546466,"eighty":3.665617,"marketCap":4568921},{"date":"2023-06-02","current":-0.263376,"twenty":-6.328294,"median":-3.514744,"eighty":3.672804,"marketCap":4429004},{"date":"2023-06-09","current":-0.260982,"twenty":-6.328294,"median":-3.451981,"eighty":3.672804,"marketCap":4388741},{"date":"2023-06-15","current":-0.27044,"twenty":-6.328294,"median":-3.403347,"eighty":3.679992,"marketCap":4547782},{"date":"2023-06-23","current":-0.320182,"twenty":-6.328294,"median":-3.291179,"eighty":3.694367,"marketCap":5384260},{"date":"2023-06-30","current":-0.290313,"twenty":-6.328294,"median":-3.169546,"eighty":3.701554,"marketCap":4881971},{"date":"2023-07-07","current":-0.248412,"twenty":-6.328294,"median":-3.138164,"eighty":3.701554,"marketCap":4177356},{"date":"2023-07-14","current":-0.311263,"twenty":-6.328294,"median":-2.981256,"eighty":3.701554,"marketCap":5234278},{"date":"2023-07-21","current":-0.269362,"twenty":-6.328294,"median":-2.934184,"eighty":3.701554,"marketCap":4529664},{"date":"2023-07-28","current":-0.281334,"twenty":-6.328294,"median":-2.75829,"eighty":3.701554,"marketCap":4730982},{"date":"2023-08-04","current":-0.269362,"twenty":-6.328294,"median":-2.54761,"eighty":3.701554,"marketCap":4529664},{"date":"2023-08-11","current":-0.269362,"twenty":-6.328294,"median":-2.470374,"eighty":3.701554,"marketCap":4529664},{"date":"2023-08-18","current":-0.257509,"twenty":-6.328294,"median":-2.4436,"eighty":3.701554,"marketCap":4578987},{"date":"2023-08-25","current":-0.271718,"twenty":-6.328294,"median":-2.398421,"eighty":3.701554,"marketCap":4831641},{"date":"2023-09-01","current":-0.249145,"twenty":-6.328294,"median":-2.359058,"eighty":3.701554,"marketCap":4430263},{"date":"2023-09-08","current":-0.243414,"twenty":-6.328294,"median":-2.338221,"eighty":3.701554,"marketCap":4328345},{"date":"2023-09-15","current":-0.229828,"twenty":-6.328294,"median":-2.317974,"eighty":3.701554,"marketCap":4086763},{"date":"2023-09-22","current":-0.226431,"twenty":-6.328294,"median":-2.286959,"eighty":3.701554,"marketCap":4026368},{"date":"2023-09-29","current":-0.231526,"twenty":-6.328294,"median":-2.258764,"eighty":3.701554,"marketCap":4116961},{"date":"2023-10-06","current":-0.209449,"twenty":-6.328294,"median":-2.255631,"eighty":3.701554,"marketCap":3724390},{"date":"2023-10-13","current":-0.226431,"twenty":-6.328294,"median":-2.244666,"eighty":3.701554,"marketCap":4026368},{"date":"2023-10-20","current":-0.199713,"twenty":-6.328294,"median":-2.196715,"eighty":3.701554,"marketCap":3551256},{"date":"2023-10-23","current":-0.208883,"twenty":-6.328294,"median":-2.196107,"eighty":3.701554,"marketCap":3714324},{"date":"2023-11-03","current":-0.175485,"twenty":-6.339984,"median":-2.161646,"eighty":3.759054,"marketCap":3120445},{"date":"2023-11-10","current":-0.17039,"twenty":-6.339984,"median":-2.130318,"eighty":3.759054,"marketCap":3029841},{"date":"2023-11-17","current":-0.159186,"twenty":-6.339984,"median":-2.127185,"eighty":3.759054,"marketCap":2844628},{"date":"2023-11-24","current":-0.173437,"twenty":-6.339984,"median":-2.109641,"eighty":3.759054,"marketCap":3099296},{"date":"2023-12-01","current":-0.174451,"twenty":-6.339984,"median":-2.086626,"eighty":3.759054,"marketCap":3117415},{"date":"2023-12-08","current":-0.185041,"twenty":-6.337061,"median":-2.066566,"eighty":3.744679,"marketCap":3306654},{"date":"2023-12-15","current":-0.16679,"twenty":-6.339984,"median":-2.036333,"eighty":3.759054,"marketCap":2980518},{"date":"2023-12-22","current":-0.17186,"twenty":-6.339984,"median":-2.005005,"eighty":3.759054,"marketCap":3071112},{"date":"2023-12-29","current":-0.176873,"twenty":-6.342906,"median":-2.004536,"eighty":3.773429,"marketCap":3160698},{"date":"2024-01-05","current":-0.168987,"twenty":-6.343289,"median":-1.988291,"eighty":3.773429,"marketCap":3019776},{"date":"2024-01-12","current":-0.160932,"twenty":-6.343289,"median":-1.918737,"eighty":3.773429,"marketCap":2875833},{"date":"2024-01-19","current":-0.143639,"twenty":-6.343671,"median":-1.894753,"eighty":3.773429,"marketCap":2566809},{"date":"2024-01-26","current":-0.132373,"twenty":-6.343289,"median":-1.880122,"eighty":3.773429,"marketCap":2365491},{"date":"2024-02-02","current":-0.130796,"twenty":-6.343289,"median":-1.718603,"eighty":3.773429,"marketCap":2337306},{"date":"2024-02-09","current":-0.121107,"twenty":-6.343289,"median":-1.687923,"eighty":3.773429,"marketCap":2164172},{"date":"2024-02-16","current":-0.152088,"twenty":-6.343289,"median":-1.678295,"eighty":3.773429,"marketCap":2717798},{"date":"2024-02-23","current":-0.17462,"twenty":-6.343289,"median":-1.662585,"eighty":3.773429,"marketCap":3120435},{"date":"2024-03-01","current":-0.188533,"twenty":-6.342906,"median":-1.650589,"eighty":3.773429,"marketCap":3369063},{"date":"2024-03-08","current":-0.156594,"twenty":-6.342906,"median":-1.633325,"eighty":3.773429,"marketCap":2798325},{"date":"2024-03-15","current":-0.168987,"twenty":-6.342906,"median":-1.621324,"eighty":3.773429,"marketCap":3019776},{"date":"2024-03-22","current":-0.152257,"twenty":-6.342906,"median":-1.587635,"eighty":3.773429,"marketCap":2720818},{"date":"2024-03-28","current":-0.258074,"twenty":-6.342906,"median":-1.509078,"eighty":3.773429,"marketCap":2566809},{"date":"2024-04-05","current":-0.283274,"twenty":-6.343289,"median":-1.475053,"eighty":3.773429,"marketCap":2817451},{"date":"2024-04-12","current":-0.272951,"twenty":-6.343289,"median":-1.471663,"eighty":3.773429,"marketCap":2714778},{"date":"2024-04-19","current":-0.235404,"twenty":-6.343289,"median":-1.409304,"eighty":3.773429,"marketCap":2341332},{"date":"2024-04-26","current":-0.233683,"twenty":-6.342906,"median":-1.393062,"eighty":3.773429,"marketCap":2324220},{"date":"2024-05-03","current":-0.234999,"twenty":-6.342906,"median":-1.371889,"eighty":3.773429,"marketCap":2337306},{"date":"2024-05-10","current":-0.238742,"twenty":-6.342906,"median":-1.353195,"eighty":3.773429,"marketCap":2374540},{"date":"2024-05-17","current":-0.216025,"twenty":-6.342906,"median":-1.34247,"eighty":3.773429,"marketCap":2367504},{"date":"2024-05-24","current":-0.213275,"twenty":-6.342906,"median":-1.32975,"eighty":3.773429,"marketCap":2337367},{"date":"2024-05-31","current":-0.217899,"twenty":-6.342906,"median":-1.322398,"eighty":3.773429,"marketCap":2388048},{"date":"2024-06-07","current":-0.213453,"twenty":-6.342906,"median":-1.290188,"eighty":3.773429,"marketCap":2339319},{"date":"2024-06-14","current":-0.252305,"twenty":-6.343289,"median":-0.312799,"eighty":3.773429,"marketCap":2765108},{"date":"2024-06-21","current":-0.21157,"twenty":-6.343671,"median":-0.305576,"eighty":3.773429,"marketCap":2318684},{"date":"2024-06-28","current":-0.211249,"twenty":-6.344819,"median":-0.300678,"eighty":3.773429,"marketCap":2315161},{"date":"2024-07-05","current":-0.213086,"twenty":-6.344819,"median":-0.293305,"eighty":3.773429,"marketCap":2335293},{"date":"2024-07-12","current":-0.213086,"twenty":-6.344819,"median":-0.287918,"eighty":3.773429,"marketCap":2335293},{"date":"2024-07-15","current":-0.218229,"twenty":-6.344819,"median":-0.2872,"eighty":3.773429,"marketCap":2391662},{"date":"2024-08-02","current":-0.224566,"twenty":-6.358314,"median":-0.281334,"eighty":3.938742,"marketCap":2461107},{"date":"2024-08-09","current":-0.209687,"twenty":-6.358314,"median":-0.277019,"eighty":3.938742,"marketCap":2298049},{"date":"2024-08-16","current":-0.230462,"twenty":-6.358314,"median":-0.275348,"eighty":3.938742,"marketCap":2254766},{"date":"2024-08-23","current":-0.24178,"twenty":-6.358314,"median":-0.272037,"eighty":3.938742,"marketCap":2365491},{"date":"2024-08-30","current":-0.23859,"twenty":-6.358314,"median":-0.270532,"eighty":3.938742,"marketCap":2334286},{"date":"2024-09-06","current":-0.244866,"twenty":-6.358314,"median":-0.269362,"eighty":3.938742,"marketCap":2395688},{"date":"2024-09-13","current":-0.227376,"twenty":-6.358314,"median":-0.269095,"eighty":3.938742,"marketCap":2224568},{"date":"2024-09-20","current":-0.25248,"twenty":-6.358314,"median":-0.267147,"eighty":3.938742,"marketCap":2470176},{"date":"2024-09-27","current":-0.293222,"twenty":-6.358314,"median":-0.265308,"eighty":3.938742,"marketCap":2868787},{"date":"2024-10-04","current":-0.277789,"twenty":-6.358314,"median":-0.26423,"eighty":3.938742,"marketCap":2717798},{"date":"2024-10-11","current":-0.334582,"twenty":-6.358314,"median":-0.26423,"eighty":3.938742,"marketCap":3273437},{"date":"2024-10-18","current":-0.287049,"twenty":-6.358314,"median":-0.26423,"eighty":3.938742,"marketCap":2808391},{"date":"2024-10-25","current":-0.267501,"twenty":-6.358314,"median":-0.26423,"eighty":3.938742,"marketCap":2617139},{"date":"2024-10-31","current":-0.271514,"twenty":-6.358314,"median":-0.263885,"eighty":3.938742,"marketCap":2656396},{"date":"2024-11-08","current":-0.250525,"twenty":-6.362565,"median":-0.263376,"eighty":3.945929,"marketCap":2451051},{"date":"2024-11-15","current":-0.262357,"twenty":-6.362565,"median":-0.263134,"eighty":3.945929,"marketCap":2566809},{"date":"2024-11-22","current":-0.229467,"twenty":-6.362565,"median":-0.260982,"eighty":3.945929,"marketCap":2244700},{"date":"2024-11-29","current":-0.241815,"twenty":-6.362565,"median":-0.26034,"eighty":3.945929,"marketCap":2365491},{"date":"2024-12-06","current":-0.22638,"twenty":-6.362565,"median":-0.258074,"eighty":3.945929,"marketCap":2214502},{"date":"2024-12-13","current":-0.219177,"twenty":-6.362565,"median":-0.257213,"eighty":3.945929,"marketCap":2144040},{"date":"2024-12-20","current":-0.210945,"twenty":-6.362565,"median":-0.255875,"eighty":3.945929,"marketCap":2063513},{"date":"2024-12-27","current":-0.288634,"twenty":-6.362565,"median":-0.255355,"eighty":3.945929,"marketCap":2823490},{"date":"2025-01-03","current":-0.68943,"twenty":-6.362565,"median":-0.255355,"eighty":3.945929,"marketCap":6744166},{"date":"2025-01-10","current":-0.46305,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":4529664},{"date":"2025-01-17","current":-0.420861,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":4116961},{"date":"2025-01-24","current":-0.423948,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":4147159},{"date":"2025-01-31","current":-0.364369,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":3564342},{"date":"2025-02-07","current":-0.340599,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":3331819},{"date":"2025-02-14","current":-0.354285,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":3465696},{"date":"2025-02-21","current":-0.339776,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":3323766},{"date":"2025-02-28","current":-0.410365,"twenty":-6.366816,"median":-0.255238,"eighty":3.953117,"marketCap":4014288},{"date":"2025-03-07","current":-0.366324,"twenty":-6.370535,"median":-0.255121,"eighty":3.960304,"marketCap":3583467},{"date":"2025-03-14","current":-0.335763,"twenty":-6.370535,"median":-0.255121,"eighty":3.960304,"marketCap":3284509},{"date":"2025-03-21","current":-0.291207,"twenty":-6.370535,"median":-0.255121,"eighty":3.960304,"marketCap":2848655},{"date":"2025-03-28","current":-0.300468,"twenty":-6.370535,"median":-0.256184,"eighty":3.715929,"marketCap":2939248},{"date":"2025-04-04","current":-0.267128,"twenty":-6.370535,"median":-0.257264,"eighty":3.593742,"marketCap":2613112},{"date":"2025-04-11","current":-0.269082,"twenty":-6.366816,"median":-0.25751,"eighty":3.529869,"marketCap":2632228},{"date":"2025-04-17","current":-0.260773,"twenty":-6.366816,"median":-0.258023,"eighty":3.495928,"marketCap":2566809},{"date":"2025-04-25","current":-0.291452,"twenty":-6.370535,"median":-0.260337,"eighty":3.394106,"marketCap":2868787},{"date":"2025-05-02","current":-0.263022,"twenty":-6.370535,"median":-0.260679,"eighty":3.310646,"marketCap":2588954},{"date":"2025-05-09","current":-0.277237,"twenty":-6.370535,"median":-0.261079,"eighty":3.244714,"marketCap":2728870},{"date":"2025-05-16","current":-0.314733,"twenty":-6.370535,"median":-0.262716,"eighty":3.156247,"marketCap":3021541},{"date":"2025-05-23","current":-0.31809,"twenty":-6.370535,"median":-0.263316,"eighty":3.054695,"marketCap":3053775},{"date":"2025-05-30","current":-0.316323,"twenty":-6.370535,"median":-0.263376,"eighty":2.952872,"marketCap":3036810},{"date":"2025-06-06","current":-0.364037,"twenty":-6.370535,"median":-0.265443,"eighty":2.674351,"marketCap":3494876},{"date":"2025-06-13","current":-0.36545,"twenty":-6.370535,"median":-0.267269,"eighty":2.572732,"marketCap":3508448},{"date":"2025-06-16","current":-0.35149,"twenty":-6.370535,"median":-0.267269,"eighty":2.563432,"marketCap":3374422}],"updateTime":1750150198535}}}